Chugai Pharmaceutical Co Ltd (DE:CUP)
FRANKFURT:CUP
CUP Stock Chart & Stats
€45.91
-€0.62(-1.51%)
At close: 4:00 PM EST
€45.91
-€0.62(-1.51%)
Day’s Range― - ―
52-Week Range€33.02 - €56.26
Previous CloseN/A
Volume105.00
Average Volume (3M)53.00
Market Cap
€67.29B
Enterprise Value€12.59T
Total Cash (Recent Filing)€850.10B
Total Debt (Recent Filing)€17.51B
Price to Earnings (P/E)27.5
Beta0.77
Next Earnings
Jul 24, 2026EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)274.78
Shares Outstanding1,679,057,600
10 Day Avg. Volume1
30 Day Avg. Volume53
Financial Highlights & Ratios
PEG Ratio2.60
Price to Book (P/B)6.70
Price to Sales (P/S)10.78
P/FCF Ratio43.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€52.33Price Target Upside13.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.68
Revenue Forecast (FY)€7.49B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained, industry-leading margins and ~22% ROE indicate durable pricing power, efficient R&D-to-commercialization, and strong operating leverage. This profitability supports long-term reinvestment in pipeline, stable dividends, and resilience through product cycles without relying on leverage.
Conservative Balance SheetExtremely low leverage and a large equity base provide structural financial flexibility: cushions patent or reimbursement shocks, enables sustained R&D spending or opportunistic bolt-on deals, and reduces refinancing risk across multi-year drug development timelines.
Strategic Roche Partnership & R&D FocusAs part of the Roche group and with close collaboration, Chugai gains scale in global development, shared regulatory expertise, and commercialization reach. This structural alliance de-risks late-stage development and accelerates global market access for its biologics and oncology portfolio.
Bears Say
Uneven Revenue Growth / Product RelianceRevenue has shown volatility, including a notable 2023 contraction and only modest re-acceleration recently. Heavy dependence on a handful of therapeutic franchises and product life-cycle timing means top-line variability can persist, complicating multi-year forecasting and investment pacing.
Variable Cash ConversionTTM operating cash below net income and prior volatility point to working-capital swings and timing effects. This can constrain actual free cash available for buybacks, special investments or higher dividends in some years despite strong accounting earnings, affecting long-term capital allocation predictability.
Balance-sheet Re-mix IndicatorsA recent decline in equity and assets, while leverage remains low, could signal capital returns, restructuring, or asset re-balancing. Over the medium term, such changes deserve monitoring as they may alter surplus capital available for R&D funding or inorganic growth priorities.
Chugai Pharmaceutical Co News
CUP FAQ
What was Chugai Pharmaceutical Co Ltd’s price range in the past 12 months?
Chugai Pharmaceutical Co Ltd lowest stock price was €33.02 and its highest was €56.26 in the past 12 months.
What is Chugai Pharmaceutical Co Ltd’s market cap?
Chugai Pharmaceutical Co Ltd’s market cap is €67.29B.
When is Chugai Pharmaceutical Co Ltd’s upcoming earnings report date?
Chugai Pharmaceutical Co Ltd’s upcoming earnings report date is Jul 24, 2026 which is in 47 days.
How were Chugai Pharmaceutical Co Ltd’s earnings last quarter?
Chugai Pharmaceutical Co Ltd released its earnings results on Apr 24, 2026. The company reported €0.378 earnings per share for the quarter, beating the consensus estimate of €0.361 by €0.016.
Is Chugai Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Chugai Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Chugai Pharmaceutical Co Ltd pay dividends?
Chugai Pharmaceutical Co Ltd does not currently pay dividends.
What is Chugai Pharmaceutical Co Ltd’s EPS estimate?
Chugai Pharmaceutical Co Ltd’s EPS estimate is 0.42.
How many shares outstanding does Chugai Pharmaceutical Co Ltd have?
Chugai Pharmaceutical Co Ltd has 1,679,057,600 shares outstanding.
What happened to Chugai Pharmaceutical Co Ltd’s price movement after its last earnings report?
Chugai Pharmaceutical Co Ltd reported an EPS of €0.378 in its last earnings report, beating expectations of €0.361. Following the earnings report the stock price went up 0.777%.
Which hedge fund is a major shareholder of Chugai Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in DE:CUP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chugai Pharmaceutical Co Ltd
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
CUP Company Deck
CUP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strongly positive financial and operational picture: record FY2025 revenue, operating profit and margin, robust FY2026 guidance, significant clinical and pipeline progress (notably NXT007, giredestrant, Enspryng, orforglipron), and disciplined cost control. Key risks were acknowledged — a serious safety event delaying Elevidys launch, biosimilar and generic pressure on legacy products (Actemra, Avastin), several project discontinuations, and some uncertainty around royalty/milestone timing and cash reduction after special dividends. On balance the call emphasized sustained growth, high profitability and a focused R&D strategy while noting manageable but material risks that warrant monitoring.View all DE:CUP earnings summariesCUP Stock 12 Month Forecast
Average Price Target
€52.33
▲(13.99% Upside)
Technical Analysis
Astellas Pharma
―
Daiichi Sankyo Company
―
Eisai Co
―
ONO Pharmaceutical Co
―
Takeda Pharmaceutical Co
―
Options Prices
Currently, No data available
---